OTTAWA, ONTARIO--(Marketwire - Sept. 20, 2012) - Collagenna Skin Care Products Inc. www.collagenna.com is pleased to announce that it has signed a marketing agreement with Legacy Research Group of Toronto, Ontario for the marketing of an innovative Natural Health Supplement which helps in the reduction of Glucose levels in blood. The product is named CinGx and is a patented combination of cinnamon and ginseng which has recently received Health Canada approval which will allow for health benefit claims as a Natural Product.
Collagenna's CEO, Michael Arnkvarn states, "We have worked with this company in the past and we have been in discussions over a certain period of time for the most effective and mutually beneficial agreement for both of us. This is a revolutionary product which is beneficial for the very common condition of high blood sugar in our North American diet. At the same time, this product shows benefits in helping prevent dementia and Alzheimer's disease. Our plan is to market product directly to consumers as well as through distribution channels. We have placed our first order of 3000 bottles and we will be ready to deliver product to our customers in 4-6 weeks. We already have some commitments from Health Food stores in the Toronto area. The magnitude of this deal has the potential to be in the millions of dollars."
A new selling website will be up shortly www.cingx.com and marketing will commence in the next 10 days. An application for FDA approval will be forthcoming once the launch will be initiated in Canada.
Collagenna Skin Care Products specializes in Anti-aging products with an emphasis on Collagen stimulation both topically and internally. The company sells its products mainly through its specialized skin care clinics through its every expanding network of distribution partners.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Collagenna Skin Care Products Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Collagenna Skin Care Products Inc. cautions you that any forward-looking information provided by or on behalf of Collagenna Skin Care Products Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Collagenna Skin Care Products Inc. actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Collagenna Skin Care Products Inc's control. In addition to those discussed in Collagenna Skin Care Products Inc's press releases, public filings, and statements by Collagenna Skin Care Products Inc's management, including, but not limited to, Collagenna Skin Care Products Inc's estimate of the sufficiency of its existing capital resources, Collagenna Skin Care Products Inc's ability to raise additional capital to fund future operations, Collagenna Skin Care Products Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Collagenna Skin Care Products Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Collagenna Skin Care Products Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.